Equities

Lucid Diagnostics Inc

LUCD:NAQ

Lucid Diagnostics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.905
  • Today's Change0.015 / 1.69%
  • Shares traded85.65k
  • 1 Year change-40.07%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.

  • Revenue in USD (TTM)2.98m
  • Net income in USD-54.53m
  • Incorporated2018
  • Employees70.00
  • Location
    Lucid Diagnostics Inc360 Madison Avenue, 25Th FloorNEW YORK 10017United StatesUSA
  • Phone+1 (212) 949-4319
  • Fax+1 (302) 655-5049
  • Websitehttps://www.luciddx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
electroCore, Inc.18.69m-16.47m42.04m68.00--9.35--2.25-2.85-2.853.130.74861.161.3054.34274,897.10-102.35-70.73-177.94-88.9682.7075.81-88.12-352.821.18--0.00--86.5774.4215.02---5.88--
United Health Products Inc0.00-1.93m42.15m6.00---------0.008-0.0080.00-0.00730.000.00--0.00-719.43-6,446.86------53.19---132,561.200.0483-15.60-----100.00---55.45------
IR-Med Inc0.00-4.91m42.92m6.00--117.59-----0.0714-0.07140.000.00520.00----0.00-228.70---310.89--------------0.3061-------3.70------
IRIDEX Corp51.87m-9.57m43.23m111.00--4.54--0.8335-0.5934-0.59343.220.58591.352.938.01467,288.30-24.95-19.54-37.31-27.4642.0442.67-18.45-15.451.35--0.00---8.964.02-26.81---24.35--
Vaso Corp81.02m4.81m43.89m300.008.341.637.560.54160.030.030.46260.15311.1020.686.03270,080.006.527.6011.1916.6262.4458.395.935.821.45--0.0043--2.181.84-57.46---22.33--
Cutera Inc212.37m-150.83m44.31m540.00------0.2087-7.57-7.5710.68-8.010.48482.424.78---34.43-20.98-43.99-29.2128.4549.47-71.02-26.072.44-46.541.62---15.865.47-83.18--86.13--
iCAD Inc17.94m-5.14m46.14m67.00--1.42--2.57-0.1982-0.08940.69151.230.40810.91992.47267,731.30-11.70-23.94-14.93-34.1485.6076.96-28.66-45.024.59--0.00---12.54-7.5329.32--23.88--
LENSAR Inc44.50m-12.27m46.96m130.00--1.47--1.06-1.13-1.133.924.000.75361.329.79342,307.70-20.78-30.97-25.12-36.9450.4551.04-27.57-52.302.36--0.00--19.2511.5727.77---42.91--
Autonomix Medical Inc0.00-10.68m46.98m3.00---------0.5055-0.50550.00-0.2649------0.00----------------------------84.50------
Lucid Diagnostics Inc2.98m-54.53m47.16m70.00------15.81-1.27-1.270.06980.25440.0735--78.5042,614.29-115.88---248.82---111.06---1,576.63--1.36--0.5579--544.03--6.24------
Icecure Medical Ltd3.23m-14.65m47.56m71.00--3.91--14.73-0.3211-0.32110.07080.2660.13860.751835.6845,478.88-62.89-54.89-76.33-68.6640.2649.87-453.76-313.193.08--0.00--4.6723.5013.70--48.10--
Nutriband Inc2.09m-5.49m49.04m13.00--6.15--23.51-0.6863-0.68630.26220.72670.24576.1515.94---64.63-55.21-72.05-66.7441.3433.32-263.05-315.870.854-82.630.0312--0.274153.43-22.35--65.57--
Milestone Scientific Inc9.48m-7.06m52.24m17.00--7.00--5.51-0.0948-0.09480.12650.09740.80250.775612.04557,570.60-60.13-55.48-80.86-74.7269.4263.97-74.93-88.941.80--0.0011--11.600.423320.41---7.99--
Cytosorbents Corp36.69m-27.54m52.55m186.00--2.78--1.43-0.5869-0.58690.77480.34860.70194.825.97197,237.50-52.69-36.00-68.27-43.5264.0868.15-75.07-62.711.21-114.700.1896--4.7910.0613.12---9.24--
Heartbeam Inc0.00-15.11m54.50m15.00--4.35-----0.6111-0.61110.000.47620.00----0.00-200.17---258.74--------------0.00-------12.94------
Data as of May 17 2024. Currency figures normalised to Lucid Diagnostics Inc's reporting currency: US Dollar USD

Institutional shareholders

4.02%Per cent of shares held by top holders
HolderShares% Held
Luminus Management LLCas of 31 Dec 2023773.25k1.60%
The Vanguard Group, Inc.as of 31 Mar 2024560.92k1.16%
Nantahala Capital Management LLCas of 31 Dec 2023149.70k0.31%
Bridgeway Capital Management LLCas of 31 Dec 2023135.00k0.28%
Geode Capital Management LLCas of 31 Dec 2023131.87k0.27%
BlackRock Fund Advisorsas of 31 Mar 202450.07k0.10%
LPL Financial LLCas of 31 Mar 202437.03k0.08%
Verition Fund Management LLCas of 31 Dec 202336.17k0.08%
Geneos Wealth Management, Inc.as of 31 Mar 202433.85k0.07%
Citadel Securities LLCas of 31 Dec 202329.64k0.06%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.